T3D Therapeutics Receives $9 Million NIH Grant to Advance Alzheimer's Clinical Trial

T3D Therapeutics, based in Research Triangle Park, NC, received a $9 million grant over four years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). The funds will be used to partially support a Phase II clinical trial of T3D-959, the company’s novel treatment for Alzheimer’s disease.